American Society of Hematology 54th Annual Meeting to be Held Dec. 8-11

The American Society of Hematology 54th Annual Meeting will be held Dec. 8-11, 2012 at the Georgia World Congress Center in Atlanta. Mayo Clinic will have six speakers, and 180 oral and poster presentations. Mayo Medical Laboratories representatives will be available in the exhibit hall at booth #1825. Stop by to learn about:

  • Thrombotic Microangiopathy (TMA)
  • Diagnostic Immunology Testing for the Hematologist
  • Hereditary Erythrocytosis
  • Lymphoma Consultation Service
  • Plasma Cell Disorders
  • Coagulation Consultations

Don't forget to follow us on Twitter and join the conversation with the hashtag #ASH12.


Below is a schedule of all Mayo Clinic speakers and presenters (Mayo Clinic names are in italics).

Education Program


3 P's In a Pod

Date/Time Dec. 8, 2012 from 4:00 – 5:30 p.m./Dec. 10, 2012 from 2:45 - 4:15 p.m.
Chair Jeffrey Lawrence Winters, MD
Speakers Gregory Grabowski, MD; Robert J. Desnick, MD, PhD; Jeffrey Lawrence Winters, MD
Objectives This session will consist of a potpourri of pathologic processes and procedures of particular interest to the practicing hematologist, all involving the letter “P”!
Event Description Dr. Gregory Grabowski will review Gaucher disease as the prototype for lysosomal storage diseases (LSD) such as Fabry, Pompe, and Niemann-Pick diseases. He will also discuss the clinical and economic success of enzyme replacement therapy in this disorder-stimulated research, development in these diseases, and the recognition of disruption of autophagy/lysosomal function in other diseases, such as age-related degenerative diseases and idiopathic hypertrophic cardiomyopathy. Dr. Robert Desnick will review the porphyrias, focusing on congenital erythropoietic porphyria (CEP), erythropoietic protoporphyria (EPP), and the recently identified X-linked protoporphyria (XLP). The diagnosis, treatment, and results of recent clinical trials will be presented. Dr. Desnick will also discuss chronic phlebotomy for Porphyria Cutanea Tarda and hematin and liver transplantation for the acute neurologic attacks in acute hepatic porphyrias. Dr. Jeffrey Winters will review basic concepts and mechanisms of plasma exchange. He will discuss issues that must be considered when prescribing or performing plasma exchange in order to ensure safe and effective therapy. He will review the “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis” as a practical tool for determining the role of plasma exchange in disease treatment.



Keeping Pace with Advances in Myeloma

Date/Time Dec. 8, 2012 from 7:30 - 9:00 a.m./Dec. 8, 2012 from 4:00 - 5:30 p.m.
Chair Antonio Palumbo, MD
Speakers Gareth J. Morgan, MD PhD; S. Vincent Rajkumar, MD; Antonio Palumbo, MD
Objectives This session will focus on recent advances in the understanding of multiple myeloma biology and the changes in the treatment of this disease after the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib. The role of transplantation in the era of novel agents will be addressed, and future therapeutic directions will be discussed. This program will report on the most effective treatment strategies available today and outline how to properly integrate them in the management of multiple myeloma.
Event Description Dr. Gareth Morgan will review the biological features of multiple myeloma. He will describe the physiological immune system development, explain the mechanisms determining molecular alterations in myeloma, and correlate these abnormalities with the evolution of the disease. He will also comment on the clinical implications of these alterations in myeloma therapy. Dr. S. Vincent Rajkumar will review the different doublet, triplet, or quadruplet drug combinations used for the treatment of newly diagnosed myeloma. He will provide efficacy and safety results of various studies and compare these approaches. He will also present preliminary results from recent studies introducing the concept of second-generation proteasome inhibitors. Dr. Antonio Palumbo will review the role of stem cell transplantation in myeloma and the clinical benefit achieved after the introduction of novel induction, consolidation, and maintenance approaches. He will discuss whether drug combinations have replaced stem cell transplantation, the risk/benefit ratio of these approaches, and the role of maintenance treatment.


Title The Spectrum of Plasma Cell Dyscrasias
Date/Time Dec. 8, 2012 from 9:30 - 11:00 a.m./Dec. 10, 2012 from 7:00 - 8:30 a.m.
Chair Morie Abraham Gertz, MD
Speaker Irene Ghobrial, MD; Giampaolo Merlini, MD; Morie Abraham Gertz, MD
Objectives This session will focus on the complex diagnostic challenges that are associated with plasma cell dyscrasias. The focus will be on those disorders that can cause diagnostic confusion and can potentially result in the incorrect treatment selection for patients. The session is aimed at busy practicing clinicians and is focused on making the correct diagnosis, determining the appropriate time to treat, and determining when to observe.
Event Description Dr. Irene Ghobrial will review the diagnostic criteria for Waldenström macroglobulinemia. While a number of disorders are associated with the monoclonal IgM protein, they are not Waldenström macröglobulinemia, underscoring the importance of taking specific, required considerations. The management of IgM and neuropathy will be discussed. Dr. Giampaolo Merlini will review the differential diagnosis of monoclonal gammopathy of undetermined significance (MGUS). Many patients with small monoclonal gammopathies are often assumed to have MGUS when in fact they fulfill the criteria of a dangerous small B-cell clone. New classification schemes for MGUS and smoldering multiple myeloma focusing on criteria for starting treatment will be reviewed. Dr. Morie Gertz will review the records of seven patients that were initially incorrectly diagnosed. He will present a detailed schema to recognize how to not overlook these entities.

Ticketed Sessions


Consultative Hematology Course

Date/Time Dec. 10, 2012 from 7:30 - 11:45 a.m.
Chairs  Lawrence A. Solberg Jr., MD, PhD; Mark A. Crowther, MD, FRCPC
Event Description Geared toward North American practitioners trained in hematology or hematology-oncology who infrequently see patients with non-malignant hematologic disorders, the 2012 Consultative Hematology Course will cover commonly encountered clinical problems that arise in everyday practice and require the expertise of a hematologist.



How I Treat: Bringing Science to Clinical Dilemmas


When to Worry about Monoclonal Gammopathy of Undetermined Significance and Smoldering Myelomas

Date/Time Dec. 8, 2012 from 11:15 a.m. - 12:15 p.m.
Speaker Robert A. Kyle, MD

Management of Myelofibrosis

Date/Time  Dec. 9, 2012 from 11:15 a.m. - 12:15 p.m.
Speaker Ruben A. Mesa, MD



Mayo Medical Laboratories

This post was authored by the Marketing Team at Mayo Medical Laboratories.